Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00643539 |
The primary objective was to compare the bacteriological efficacy at Day 10 of azithromycin pediatric suspension (20 mg/kg/day once daily for 3 consecutive days) versus amoxicillin pediatric suspension (50 mg/kg/day in 2 doses for 6 consecutive days) in children aged 3-15 years with Group A streptococcal acute pharyngitis/tonsillitis. Secondary objectives were assessments of bacteriological efficacy at Day 30 and clinical efficacy at Day 10 and Day 30.
Condition | Intervention | Phase |
---|---|---|
Tonsillitis |
Drug: Zithromax Drug: Clamoxyl |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter, Open, Randomized Comparative Trial To Compare Bacteriological And Clinical Efficacy Of Azithromycin Versus Amoxicillin In Children With Streptococcus Tonsillitis |
Enrollment: | 360 |
Study Start Date: | December 2002 |
Study Completion Date: | July 2003 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Clamoxyl
Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
|
2: Experimental |
Drug: Zithromax
azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
|
Ages Eligible for Study: | 3 Years to 15 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Outpatients with an acute pharyngitis erythematous or erythematopultaceous with modification of pharynx aspect and fever of ≥38° C, and patients either with or without spontaneous pharyngeal pain or upon swallowing and enlargement of the cervical lymph node (mandibular area) were eligible for inclusion. All subjects should have had a positive rapid strep test and a positive culture for Group A beta-hemolytic streptococcus.
Exclusion Criteria:
Patients with pseudomembranous, vesicular, ulcerous or ulceronecrotic pharyngitis were excluded.
France | |
Pfizer Investigational Site | |
BRIVE, France, 19100 | |
Pfizer Investigational Site | |
CHAMBERY, France, 73000 | |
Pfizer Investigational Site | |
ESSEY LES NANCY, France, 54270 | |
Pfizer Investigational Site | |
VENCE, France, 06140 | |
Pfizer Investigational Site | |
CANNES LA BOCA, France, 06150 | |
Pfizer Investigational Site | |
DIJON, France, 21000 | |
Pfizer Investigational Site | |
AUCH, France, 32000 | |
Pfizer Investigational Site | |
TRESSES, France, 33370 | |
Pfizer Investigational Site | |
COMBS LA VILLE, France, 77380 | |
Pfizer Investigational Site | |
NOGENT SUR MARNE, France, 94130 | |
Pfizer Investigational Site | |
SAINT QUENTIN, France, 02100 | |
Pfizer Investigational Site | |
BOULOGNE, France, 92100 | |
Pfizer Investigational Site | |
CHALONS EN CHAMPAGNE, France, 51000 | |
Pfizer Investigational Site | |
SALON DE PROVENCE, France, 13300 | |
Pfizer Investigational Site | |
LES SABLES D`OLONNE, France, 85100 | |
Pfizer Investigational Site | |
MASSY, France, 91300 | |
Pfizer Investigational Site | |
TOURS, France, 37000 | |
Pfizer Investigational Site | |
MARSEILLE, France, 13006 | |
Pfizer Investigational Site | |
PARIS, France, 75020 | |
Pfizer Investigational Site | |
PARIS, France, 75019 | |
Pfizer Investigational Site | |
LES ULIS, France, 91940 | |
Pfizer Investigational Site | |
DRAGUIGNAN, France, 83300 | |
Pfizer Investigational Site | |
Champigny sur Marne, France, 94500 | |
Pfizer Investigational Site | |
SAINT MARCEL, France, 71380 | |
Pfizer Investigational Site | |
MARSEILLE, France, 13014 | |
Pfizer Investigational Site | |
STRASBOURG, France, 67100 | |
Pfizer Investigational Site | |
SELESTAT, France, 67600 | |
Pfizer Investigational Site | |
ANCENIS, France, 44150 | |
Pfizer Investigational Site | |
VAROIS ET CHAIGNOT, France, 21490 | |
Pfizer Investigational Site | |
PARIS, France, 75015 | |
Pfizer Investigational Site | |
BREST, France, 29200 | |
Pfizer Investigational Site | |
THIONVILLE, France, 57100 | |
Pfizer Investigational Site | |
VANDOEUVRE LES NANCY, France, 54500 | |
Pfizer Investigational Site | |
LAGNY, France, 77400 | |
Pfizer Investigational Site | |
MEYSIEU, France, 69330 | |
Pfizer Investigational Site | |
DRAGUIGNAN, France, 33170 | |
Pfizer Investigational Site | |
MILLERY, France, 69390 | |
Pfizer Investigational Site | |
PARIS, France, 75004 | |
Pfizer Investigational Site | |
PARIS, France, 75005 | |
Pfizer Investigational Site | |
LEVALLOIS PERRET, France, 92300 | |
Pfizer Investigational Site | |
MEUDON LA FORET, France, 92360 | |
Pfizer Investigational Site | |
ASNIERES SUR SEINE, France, 92600 | |
Pfizer Investigational Site | |
Sartrouville, France, 78500 | |
Pfizer Investigational Site | |
Versailles, France, 78000 | |
Pfizer Investigational Site | |
MARSEILLE, France, 13013 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A0661037 |
Study First Received: | March 19, 2008 |
Last Updated: | March 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00643539 |
Health Authority: | United States: Food and Drug Administration |
Amoxicillin Otorhinolaryngologic Diseases Respiratory Tract Diseases Respiratory Tract Infections Streptococcal Infections |
Azithromycin Tonsillitis Stomatognathic Diseases Pharyngeal Diseases |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Pharmacologic Actions |